Free Trial
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel
NASDAQ:ALMS

Alumis Q3 2026 Earnings Date & Estimates

Alumis logo
$6.06 -0.50 (-7.62%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$6.25 +0.19 (+3.14%)
As of 08:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alumis is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. The conference call is scheduled for November 13, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Alumis in Q3 2026

Alumis is expected to post earnings of -$0.73 per share on revenue of $1.90 million. In the same quarter a year earlier Alumis reported -$1.06 per share on revenue of $2.07 million. Alumis last reported on August 13, 2026, posting -$1.11 per share and missing the -$0.7670 consensus estimate. Alumis has beaten the consensus EPS estimate in 0 of its last 7 quarters.

Consensus Estimates

Consensus EPS
-$0.73
Expected Revenue
$1.90 million
Prior-Year EPS
-$1.06
Prior-Year Revenue
$2.07 million
Expected Revenue Growth
-8.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.11 (Missed by -$0.3430)
Last Quarter Revenue
$1.66 million
EPS Beat Rate
0 of last 7 quarters

Prepare for the Q3 2026 Call

Alumis Q3 2026 Earnings FAQ

Alumis (NASDAQ:ALMS) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Alumis' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Alumis to post earnings of -$0.73 per share for Q3 2026.

The consensus revenue estimate for Alumis is $1.90 million for Q3 2026.

Alumis Earnings Headlines

Alumis Inc. (ALMS) - What Are Investment Firms Saying About This Stock?
October 12 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109156
Alumis Reports Positive Phase 3 Data With Envudeucitinib
October 9, 2026  |  rttnews.comhttps://www.rttnews.com/3697875/alumis-reports-positive-phase-3-data-with-envudeucitinib.aspx
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
October 15 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Alumis Says Phase 3 Data From Plaque Psoriasis Program Reiterate Treatment's Potential as 'Leading' Oral Therapy
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/alumis-says-phase-3-data-084051962.html
Alumis Shares New Phase 3 Psoriasis Data For Envudeucitinib; Stock Up
October 9, 2026  |  rttnews.comhttps://www.rttnews.com/3697905/alumis-shares-new-phase-3-psoriasis-data-for-envudeucitinib-stock-up.aspx
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
October 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/09/3377840/0/en/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib-rapidly-and-durably-improved-psoriasis-burden-across-scalp-itch-and-quality-of-life-measures.html
See More Alumis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alumis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alumis and other key companies, straight to your email.

About Alumis

Alumis (NASDAQ:ALMS), Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases. The company’s research centers on selective allosteric inhibitors of tyrosine kinase 2 (TYK2), a protein involved in signaling pathways that regulate inflammation and immune responses.

Alumis’ lead product candidate is ESK-001, an oral, highly selective TYK2 inhibitor being evaluated in inflammatory and autoimmune conditions, including plaque psoriasis, psoriatic arthritis and systemic lupus erythematosus. The company is also advancing additional pipeline programs, including A-005, an investigational TYK2 inhibitor designed to reach the central nervous system.

Alumis was formerly known as Esker Therapeutics and is headquartered in the United States. Its development programs are intended to support the treatment of patients with immune dysfunction in multiple global markets, subject to clinical and regulatory success.

View Alumis Profile
Earnings Tools